Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Between being a cast member on The Real Housewives of New Jersey, starring in the latest season of the hit competition show ...

But while basic research continues slowly, a flood of Ozempic competitors are rushing to market. Some of them may work even better than Ozempic at causing weight loss. Mounjaro, from a company ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

In 2020, Ozempic was granted additional approval to ... with type 2 diabetes with known heart disease. Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's (LLY) tirzepatide ...